HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND ® artificial ...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable ongoing efficacy results from the eight-month follow-up visit for the fourth patient ...
Provides Enrollment Update for Phase 1 Study in Late-Stage Non-small Cell Lung Cancer At the 12-month post-treatment follow-up visit, the first patient in Deltacel-01 had a 33.33% reduction in tumor ...
RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion(R) X1 platform with SCINTIX(R) biology-guided radiotherapy at Beverly Hills Cancer Center ...
HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable early efficacy results from the first patient enrolled in the Phase 1 Deltacel-01 ...
HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (KRBP) (“Kiromic” or the “Company”) reports favorable ongoing efficacy results from follow-up visits for Patient 4 and Patient 6 in its Deltacel-01 ...
Beverly Hills Oncology Medical Group d/b/a Beverly Hills Cancer Center was hit with a data breach class action on Nov. 7 in California Superior Court for Los Angeles County. The suit, brought by ...
Beverly Hills Cancer Center is the first of up to four prestigious clinical sites expected to evaluate Deltacel™ (KB-GDT-01) in patients with non-small cell lung cancer “The clinical trial agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback